Abstract
In 1999, due to high trimethoprim-sulfamethoxazole (TMP-SMX) resistance rates in Escherichia coli (E. coli), Denver Health decided to use levofloxacin as the initial therapy for urinary tract infections (UTIs). This retrospective case-control study was performed on a subset of patients with urine cultures positive for E. coli during 2005, and evaluated the effects of that switch 6 years later. Levofloxacin prescriptions per 1000 outpatient visits and levofloxacin resistance in outpatient E. coli were evaluated over time.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
